The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).
 
Bunpei Miyazaki
No Relationships to Disclose
 
Nami Shirakawa
No Relationships to Disclose
 
Minako Sugiyama
No Relationships to Disclose
 
Ayumu Arakawa
Research Funding - Chugai Pharma (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen
 
Yayoi Ando
No Relationships to Disclose
 
Kenta Anjo
Employment - Abbvie (I)
Honoraria - Astellas Pharma; Takeda (I)
 
Yoko Kai
No Relationships to Disclose
 
Yukari Hoshina
No Relationships to Disclose
 
Junki Mizusawa
Employment - Pfizer (I)
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Taro Shibata
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; CMIC Co., Ltd.; Kyowa Kirin Co., Ltd.; m3.com
 
Natsuko Tsuda Okita
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Chitose Ogawa
Research Funding - Daiichi Sankyo; Lilly Japan; OHARA Pharmaceutical Co.,Ltd.; Ono Pharmaceutical